AIM: To analyze the effect of chemotherapeutic drugs and specific kinase inhibitors, in combination with the death receptor ligand tumor necrosis factor-related apoptosis inducing ligand (TRAIL), on overcoming TRAIL resistance in hepatocellular carcinoma (HCC) and to study the efficacy of agonistic TRAIL antibodies, as well as the commitment of antiapoptotic BCL-2 proteins, in TRAIL-induced apoptosis. METHODS: Surface expression of TRAIL receptors (TRAIL-R1-4) and expression levels of the antiapoptotic BCL-2 proteins MCL-1 and BCL-x(L) were analyzed by flow cytometry and Western blotting, respectively. Knock-down of MCL-1 and BCL-x(L) was performed by transfecting specific small interfering RNAs. HCC cells were treated with kinase inhibitors and chemotherapeutic drugs. Apoptosis induction and cell viability were analyzed via flow cytometry and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. RESULTS: TRAIL-R1 and -R2 were profoundly expressed on the HCC cell lines Huh7 and Hep-G2. However, treatment of Huh7 and Hep-G2 with TRAIL and agonistic antibodies only induced minor apoptosis rates. Apoptosis resistance towards TRAIL could be considerably reduced by adding the chemotherapeutic drugs 5-fluorouracil and doxorubicin as well as the kinase inhibitors LY294002 [inhibition of phosphoinositol-3-kinase (PI3K)], AG1478 (epidermal growth factor receptor kinase), PD98059 (MEK1), rapamycin (mammalian target of rapamycin) and the multi-kinase inhibitor Sorafenib. Furthermore, the antiapoptotic BCL-2 proteins MCL-1 and BCL-x(L) play a major role in TRAIL resistance: knock-down by RNA interference increased TRAIL-induced apoptosis of HCC cells. Additionally, knock-down of MCL-1 and BCL-x(L) led to a significant sensitization of HCC cells towards inhibition of both c-Jun N-terminal kinase and PI3K. CONCLUSION: Our data identify the blockage of survival kinases, combination with chemotherapeutic drugs and targeting of antiapoptotic BCL-2 proteins as promising ways to overcome TRAIL resistance in HCC.
AIM: To analyze the effect of chemotherapeutic drugs and specific kinase inhibitors, in combination with the death receptor ligand tumornecrosis factor-related apoptosis inducing ligand (TRAIL), on overcoming TRAIL resistance in hepatocellular carcinoma (HCC) and to study the efficacy of agonistic TRAIL antibodies, as well as the commitment of antiapoptotic BCL-2 proteins, in TRAIL-induced apoptosis. METHODS: Surface expression of TRAIL receptors (TRAIL-R1-4) and expression levels of the antiapoptotic BCL-2 proteins MCL-1 and BCL-x(L) were analyzed by flow cytometry and Western blotting, respectively. Knock-down of MCL-1 and BCL-x(L) was performed by transfecting specific small interfering RNAs. HCC cells were treated with kinase inhibitors and chemotherapeutic drugs. Apoptosis induction and cell viability were analyzed via flow cytometry and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. RESULTS:TRAIL-R1 and -R2 were profoundly expressed on the HCC cell lines Huh7 and Hep-G2. However, treatment of Huh7 and Hep-G2 with TRAIL and agonistic antibodies only induced minor apoptosis rates. Apoptosis resistance towards TRAIL could be considerably reduced by adding the chemotherapeutic drugs 5-fluorouracil and doxorubicin as well as the kinase inhibitors LY294002 [inhibition of phosphoinositol-3-kinase (PI3K)], AG1478 (epidermal growth factor receptor kinase), PD98059 (MEK1), rapamycin (mammalian target of rapamycin) and the multi-kinase inhibitor Sorafenib. Furthermore, the antiapoptotic BCL-2 proteins MCL-1 and BCL-x(L) play a major role in TRAIL resistance: knock-down by RNA interference increased TRAIL-induced apoptosis of HCC cells. Additionally, knock-down of MCL-1 and BCL-x(L) led to a significant sensitization of HCC cells towards inhibition of both c-Jun N-terminal kinase and PI3K. CONCLUSION: Our data identify the blockage of survival kinases, combination with chemotherapeutic drugs and targeting of antiapoptotic BCL-2 proteins as promising ways to overcome TRAIL resistance in HCC.
Authors: M MacFarlane; S Inoue; S L Kohlhaas; A Majid; N Harper; D B J Kennedy; M J S Dyer; G M Cohen Journal: Cell Death Differ Date: 2005-07 Impact factor: 15.828
Authors: Robert F Kelley; Klara Totpal; Stephanie H Lindstrom; Mary Mathieu; Karen Billeci; Laura Deforge; Roger Pai; Sarah G Hymowitz; Avi Ashkenazi Journal: J Biol Chem Date: 2004-11-01 Impact factor: 5.157
Authors: Maria Gómez-Benito; Maria José Martinez-Lorenzo; Alberto Anel; Isabel Marzo; Javier Naval Journal: Exp Cell Res Date: 2007-03-30 Impact factor: 3.905
Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312
Authors: M Siegemund; N Pollak; O Seifert; K Wahl; K Hanak; A Vogel; A K Nussler; D Göttsch; S Münkel; H Bantel; R E Kontermann; K Pfizenmaier Journal: Cell Death Dis Date: 2012-04-12 Impact factor: 8.469
Authors: Christian L Barrett; Richard B Schwab; HyunChul Jung; Brian Crain; Daniel J Goff; Catriona H M Jamieson; Patricia A Thistlethwaite; Olivier Harismendy; Dennis A Carson; Kelly A Frazer Journal: PLoS One Date: 2013-03-20 Impact factor: 3.240
Authors: Vivek Subbiah; Robert E Brown; Jamie Buryanek; Jonathan Trent; Avi Ashkenazi; Roy Herbst; Razelle Kurzrock Journal: Mol Cancer Ther Date: 2012-08-20 Impact factor: 6.009
Authors: Bruno Christian Koehler; Anna-Lena Scherr; Stephan Lorenz; Toni Urbanik; Nicole Kautz; Christin Elssner; Stefan Welte; Justo Lorenzo Bermejo; Dirk Jäger; Henning Schulze-Bergkamen Journal: PLoS One Date: 2013-10-03 Impact factor: 3.240
Authors: Bruno Christian Koehler; Adam Jassowicz; Anna-Lena Scherr; Stephan Lorenz; Praveen Radhakrishnan; Nicole Kautz; Christin Elssner; Johanna Weiss; Dirk Jaeger; Martin Schneider; Henning Schulze-Bergkamen Journal: BMC Cancer Date: 2015-11-19 Impact factor: 4.430